Results 71 to 80 of about 662,207 (147)

Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome
Background Cancer patients with diabetes are at increased risk for cardiovascular diseases due to common risk factors and well-documented drug-associated cardiotoxicity. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown cardiovascular benefits
Hsiao-Huai Kuo, Kuang-Te Wang, Hsin-Hao Chen, Zih-Yin Lai, Po-Lin Lin, Yung-Jen Chuang, Lawrence Yu-Min Liu   +6 more
doaj   +1 more source

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEARTResearch in context

The Lancet Regional Health. Europe
Summary: Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce rates of heart failure hospitalisations and cardiovascular death in patients with type 2 diabetes and prior cardiovascular disease.
Hans Christian Rosén, Moman A. Mohammad, Tomas Jernberg, Stefan James, Jonas Oldgren, David Erlinge   +5 more
doaj   +1 more source

Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction

ESC Heart Failure
Aims To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in ...
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, John G.F. Cleland, Ninian N. Lang, Mark C. Petrie, Michele Robertson, Ian Ford   +7 more
doaj   +1 more source

Impact of SGLT2 ınhibitors on nutritional and ımmunologic status in chronic heart failure

BMC Cardiovascular Disorders
Background The prognostic nutritional index (PNI), combining serum albumin and lymphocyte count, is a validated marker of nutritional-inflammatory status and an independent predictor of outcomes in heart failure (HF).
Meltem Altınsoy, Fadime Bozduman, Çağatay Tunca, Enes Üçgül, Hüseyin Demirci   +4 more
doaj   +1 more source

An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients

Therapeutics and Clinical Risk Management, 2016
Yaowen Wang,1 Xueting Hu,2 Xueying Liu,3 Zengqi Wang2 1Department of Clinical Laboratory, Weifang People’s Hospital, 2Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, 3Department of Clinical Laboratory, The Third ...
Wang Y, Hu X, Liu X, Wang Z
doaj  

SGLT2 Inhibitor Empagliflozin Reduces Circulating Monocyte-Platelet Aggregates: A Pilot Study. [PDF]

Circulation
Safa BI, Oakes JM, Simmons JD, Nian H, Kirk LA, Cassidy AC, Olson EC, Hatem Z, Warren CM, Gonzalez MS, Amin T, Sheng Q, Matta A, Zhu L, Hairan W, Howard SE, Flynn CR, Stier MT, Wilfong EM, Rathmell JC, Cahill KN, Brown JD, Beckman JA, Gabriel CL, Freedman JE, Luther JM, Bailin SS, Wanjalla CN, Koethe JR, Kalams SA, Mashayekhi M.   +30 more
europepmc   +1 more source

Association Between SGLT2 Inhibitor Therapy and the Incidence of Tinnitus in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Background: Numerous studies have demonstrated the beneficial effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiovascular and renal outcomes in patients with heart failure and chronic kidney disease.
Simon Bode, Karel Kostev, David Ulrich Seidel   +2 more
core   +1 more source

Rare Hereditary Cardiac Amyloidosis Treated With SGLT2 Inhibitor: Beyond ATTR/AL. [PDF]

JACC Case Rep
Voran JC, Radić Ž, Kilian LS, Braun F, Röcken C, Frank D, Seoudy H.   +6 more
europepmc   +1 more source

Recurrent Euglycemic Diabetic Ketoacidosis Weeks After SGLT2 Inhibitor Cessation: A Case Report. [PDF]

Case Rep Endocrinol
Mansour C, Katrib E, Mansour M, Fares M.
europepmc   +1 more source

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

, 2014
Michael A Nauck Department of Internal Medicine, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany Abstract: The importance of the kidney's role in glucose homeostasis has gained wider understanding in recent years.
Nauck MA
core